IBA renews Spanish radiopharmaceuticals contract

Published: 4-Jan-2011

Four-year deal with Servicio Andaluz de Salud worth €34m


IBA, a global developer of radiopharmaceuticals used in molecular imaging, has renewed its exclusive four-year contract with Servicio Andaluz de Salud in Andalusia, Spain.

Under the terms of the agreement, IBA, based in Louvain-la-Neuve, Belgium will supply all radiopharmaceuticals for the 12 nuclear medicine departments located in the public hospitals in Andalusia, starting from the middle of this month. This includes both Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) radiopharmaceuticals from IBA’s portfolio.

The new contract is valued at nearly €34m over a period of four years. IBA says its renewal is a central element of its business development in Spain, where Andalusia represents approximately a fifth of the Spanish radiopharmaceuticals market.

‘Through this contract, we will further support the development of personalised medicine in Spain, and the earlier and more accurate detection of major diseases,’ said Pierre Mottet, chief executive of IBA.

IBA claims to have the only global PET network in the industry, with 57 PET facilities, and the most modern SPECT facility. The company distributes its products in the US, Europe and India.

With radiopharmaceutical innovation capabilities that address indications in oncology, cardiology and neurology, in PET, SPECT and therapy, IBA has engineered a unique product portfolio and pipeline of diagnostic tracers aimed at contributing to the development of personalised medicine and making molecular imaging a major discipline in healthcare.

You may also like